CV Therapeutics Names Lewis Stuart Senior Vice President, Commercial Operations
July 16 2007 - 4:01PM
PR Newswire (US)
PALO ALTO, Calif., July 16 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) announced today the appointment of
Lewis Stuart as senior vice president, commercial operations. Mr.
Stuart had served as vice president, sales since joining the
company in July 2003. He succeeds David McCaleb who will continue
to serve as a consultant to the company. "Lewis has done an
outstanding job assembling our cardiovascular sales team, creating
the related infrastructure and building a strong foundation for a
growing Ranexa franchise. I am looking forward to working with
Lewis in his expanded role as we move towards some very important
commercial milestones, including the potential expansion and
improvement of Ranexa labeling in 2008," said Louis G. Lange,
chairman and chief executive officer of CV Therapeutics. "I also
want to thank David McCaleb for his enormous contributions to CV
Therapeutics over the past decade. David returns to consulting
having built an exceptional commercial organization dedicated to
bringing an important new medicine, Ranexa, to patients and
physicians every day," Lange added. "I am extremely excited by this
opportunity and honored to lead the commercial organization in
growing our business while delivering value to patients, physicians
and shareholders," Stuart said. Mr. Stuart has more than 25 years
of sales and marketing experience. Since 1990, he has held senior
U.S. and European sales and marketing positions within the
biotechnology sector, including six years as vice president, sales
at Agouron Pharmaceuticals, Inc., a Pfizer company. There, he
fielded an HIV sales organization to launch Agouron's lead product,
Viracept(R), which became the most widely prescribed protease
inhibitor in the U.S. Earlier in Mr. Stuart's career, he directed
the sales teams for several cardiovascular products at Bristol
Myers Squibb, Inc., including Capoten(R), an ACE inhibitor
prescribed to treat high blood pressure and congestive heart
failure, and Corgard(R), a beta blocker prescribed to treat angina
and high blood pressure. About CV Therapeutics CV Therapeutics,
Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company focused on applying molecular cardiology
to the discovery, development and commercialization of novel, small
molecule drugs for the treatment of cardiovascular diseases. CV
Therapeutics' approved product, Ranexa(R) (ranolazine
extended-release tablets), is indicated for the treatment of
chronic angina in patients who have not achieved an adequate
response with other antianginal drugs, and should be used in
combination with amlodipine, beta-blockers or nitrates. CV
Therapeutics also has other clinical and preclinical drug
development candidates and programs, including regadenoson, which
is being developed for potential use as a pharmacologic stress
agent in myocardial perfusion imaging studies, and CVT-6883, which
is being developed as a potential treatment for cardiopulmonary
diseases. Regadenoson and CVT-6883 have not been determined by any
regulatory authorities to be safe or effective in humans for any
use. Except for the historical information contained herein, the
matters set forth in this press release are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially, including
operating losses and fluctuations in operating results; capital
requirements; regulatory review and approval of our products;
dependence on Ranexa; special protocol assessment agreement for
Ranexa; the conduct and timing of clinical trials;
commercialization of products; market acceptance of products;
product labeling; concentrated customer base; and other risks
detailed from time to time in CV Therapeutics' SEC reports,
including its Quarterly Report on Form 10-Q for the quarter ended
March 31, 2007. CV Therapeutics disclaims any intent or obligation
to update these forward-looking statements. DATASOURCE: CV
Therapeutics, Inc. CONTACT: John Bluth, Senior Director, Corporate
Communications & Investor Relations of CV Therapeutics, Inc.,
+1-650-384-8850 Web site: http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024